Successful treatment of refractory hemolytic uremic syndrome with intravenous gamma-immunoglobulin therapy / 대한내과학회지
Korean Journal of Medicine
;
: 431-435, 2002.
Article
in Korean
| WPRIM
| ID: wpr-11150
ABSTRACT
The hemolytic uremic syndrome (HUS) is a clinical syndrome defined by the presence of thrombocytopenia, microangiopathic hemolytic anemia and acute renal failure with or without a clinically apparent etiology. The conventional treatment of choice is plasmapheresis as a first-line therapy. Most patients respond to plasmapheresis whereas some patients are refractory to the therapy. The second-line therapy is not well established although various therapies such as steroid, vincristine, intravenous immunoglobulin have been suggested. The intravenous immunoglobulin therapy in refractory hemolytic-uremic syndrome have rarely been successful in complete remission. We report a case of refractory HUS in a 48 year-old man who developed hemolytic anemia, thrombocytopenia, acute renal failure and ischemic retinopathy. The patient was refractory to plasmapheresis as a first-line therapy. The patient received intravenous immunoglobulin therapy as a second-line therapy after 8 days of plasmapheresis, which subsequently resulted in a complete remission of refractory HUS. The complete remission using immunoglobulin in HUS has not been previously reported in Korea.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombocytopenia
/
Vincristine
/
Immunoglobulins
/
Immunization, Passive
/
Plasmapheresis
/
Acute Kidney Injury
/
Hemolytic-Uremic Syndrome
/
Anemia, Hemolytic
/
Korea
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS